Remission in systemic lupus erythematosus: Durable remission is rare

Annals of the Rheumatic Diseases

Volumn 76, Issue 3, 2017, Pages 547-553

  Wilhelm, Theresa R ^a,b   Magder, Laurence S ^c   Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Copenhagen   (Denmark)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Disease Activity; Outcomes research; Systemic Lupus Erythematosus

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; PREDNISONE; ANTIINFLAMMATORY AGENT; ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DNA; IMMUNOSUPPRESSIVE AGENT;

ADULT; AFRICAN AMERICAN; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LUPUS ERYTHEMATOSUS CELL TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; PROSPECTIVE STUDY; RELAPSE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; BLOOD; DISEASE FREE SURVIVAL; ETHNOLOGY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; TIME FACTOR;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINUCLEAR; COMPLEMENT C3; COMPLEMENT C4; DISEASE-FREE SURVIVAL; DNA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREDNISONE; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; TIME FACTORS;

EID: 84984659001     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209489     Document Type: Article

References (26)

1. Barr SG, Zonana-Nacach A, Magder LS, et al. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999;42:2682-8.
2. Nossent J, Kiss E, Rozman B, et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010;19:949-56.
3. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis 2015;74:2117-22.
4. Steiman AJ, Urowitz MB, Ibañez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014;41:1808-16.
5. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
6. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67.
7. Dubois EL. Systemic lupus erythematosus: recent advances in its diagnosis and treatment. Ann Intern Med 1956;45:163-84.
8. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. Computer analysis of 520 cases. JAMA 1964;190:104-11.
9. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979;66:210-15.
10. Tozman EC, Urowitz MB, Gladman DD. Prolonged complete remission in previously severe SLE. Ann Rheum Dis 1982;41:39-40.
11. Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol 1985;12:916-18.
12. Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005;32:1467-72.
13. Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine (Baltimore) 1996;75:88-98.
14. Conti F, Ceccarelli F, Perricone C, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: a 2-year follow-up study. PLoS ONE 2012;7:e45934.
15. Formiga F, Moga I, Pac M, et al. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:724-7.
16. Steiman AJ, Gladman DD, Ibañez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012;64:511-18.
17. Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.
18. van Vollenhoven RF, Aranow C, Bertsias G, et al. Remission in SLE: consensus findings from a large international panel on definitions of remission in SLE (DORIS) [abstract]. Ann Rheum Dis 2015;74(Suppl 2):P103.
19. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13.
20. Panaccione R, Colombel JF, Louis E, et al. Evolving definitions of remission in Crohn's disease. Inflamm Bowel Dis 2013;19:1645-53.
21. Mina R, Klein-Gitelman MS, Ravelli A, et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012;64:683-93.
22. Thamer M, Hernán MA, Zhang Y, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-4.
23. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 2012;51:1145-53.
24. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708-19.
25. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
26. Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004;50:2048-65.